Comparative Pharmacology
Head-to-head clinical analysis: FML FORTE versus PREDNISOLONE EYE DROPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FML FORTE versus PREDNISOLONE EYE DROPS.
FML FORTE vs Prednisolone Eye Drops
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. This results in suppression of inflammation, immune response, and fibroblast proliferation.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators such as prostaglandins and leukotrienes.
1 drop of 0.25% ophthalmic suspension in the conjunctival sac of the affected eye(s) every 4 hours. In severe conditions, 1 drop every 2 hours initially, taper as response is achieved.
Instill 1-2 drops into the conjunctival sac of the affected eye(s) four times daily. In severe cases, dosing may be initiated with 1-2 drops every 1-2 hours and tapered upon improvement.
None Documented
None Documented
Plasma terminal elimination half-life is approximately 3-4 hours (range 2-6 hours) for fluorometholone alcohol; clinical effects may persist longer due to tissue retention.
Plasma: 2-4 hours; tissue effects persist 18-36 hours. Clinically, duration of adrenal suppression may exceed plasma half-life.
Eliminated primarily via hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 60-70%, with about 30-40% excreted in feces via bile.
Renal (primarily as metabolites): ~70% after oral dose; unchanged drug: <20%. Biliary/fecal: minor.
Category C
Category A/B
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid